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To the Editor:
We would like to thank Dr. Giannini and Dr. Sava-
rino for their interest in our article and we appreciate
their comments. The clinical status of hepatitis C virus
(HCV) infection in terms of the severity of histopathol-
ogy is lacking in our study [1]. It is indeed neither
appropriate nor possible to undergo liver biopsy for
more than 11,000 residents in a large-scale study.
Based on the cross-sectional survey in our commu-
nity-based study, we found HCV-viremic patients had
lower serum lipid levels than anti-HCV-negative or
anti-HCV-positive (but non-viremic) individuals which
provided strong evidence of the association between
HCV viremia and lower serum lipid levels. Further-
more, with the advantage of a large scale study, our re-
port demonstrated the impact of HCV viremia among
anti-HCV positive individuals. We also observed hepa-
titis B virus surface antigen positivity was indepen-
dently associated with low serum lipid levels by
multivariate analysis. The residents enrolled were aged
40–65 years and around 10% of them, according to
previous studies, may be positive for hepatitis B e anti-
gen which has been recognized to be strongly associ-
ated with an increased risk of active cirrhosis [2,3]. In
addition, we have also observed a reciprocal viral inter-
action between hepatitis B virus (HBV) and HCV after
interferon-alpha/ribavirin therapy [4]. Hence, HBV
infection might play a less important role among
anti-HCV-positive subjects, particularly among the
HCV viremic patients in our study. Nevertheless, the
lack of HBV DNA is an important limitation in our
study to validate the association between serum lipid
levels and the severity as well as viral load of chronic
HBV infection.
Recently, the association between cholesterol meta-
bolic pathway and the life cycle in terms of HCV pro-
duction, secretion and entry by human hepatocytes has
been reported [5,6]. HCV replicates on membrane vesi-
cles involved in the assembly and secretion of very
low-density lipoproteins and the low density lipoprotein
receptor involved in HCV entry were observed [7,8].
Incidentally the development of drugs that target the
cholesterol or lipoprotein metabolism and might be use-
ful in treating HCV infection by inhibition of HCV
RNA replication or production of HCV particles from
infected cells is still ongoing, although their safety pro-
ﬁles and beneﬁts require more suﬃcient evidence
[5,9,10]. Accordingly, we believe our epidemiologic
study, also taking the viral genotype into consideration,
implicates an evident association between HCV RNA
status and serum lipids. We deem it necessary at the
same time to investigate the mechanisms of interaction
between HCV and lipids.
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Interpreting liver stiﬀness in the cirrhotic range
To the Editor:
The review by Castera et al. [1] presents signiﬁcant
interest to the community as it reports a non-invasive
evaluation of liver ﬁbrosis using transient elastography
(TE). Indeed TE is becoming an important tool in the fu-
ture practice of hepatology to assess hepatic ﬁbrosis in pa-
tients with chronic liver diseases. The optimal cut-oﬀ
value for the diagnosis of cirrhosis suggested from the
summary ROC was 13.01 kPa [2] with range from
10.3 kPa in chronic hepatitis B to 17.3 kPa in chronic
cholestatic diseases. According to these results, TE can
be used in clinical practice as an excellent tool for the con-
ﬁrmation of cirrhosis when other clinical signs and exam-
inations are non-decisive.
Recently, we had the opportunity to examine a liver
biopsy (January 2008) taken from a 54 year old dia-
betic, hyperlipidemic patient, with a past history of
myocardial infarction (in 1993 and 1996), triple coro-
nary bypasses (1997), and implantation of a cardiac
deﬁbrillator (2004). This patient was treated with a
long list of medications including diuretics, sugar low-
ering agents, hypotensive drugs. In November 2007
and January 2008, the patient underwent 2 TE satisfac-
tory measurements (Fibroscan) which were surprisingly
high (14.3 and 34.8 kPa, respectively) consistent with
the diagnosis of cirrhosis possibly related to NASH be-
cause of a raised BMI (28), increased GGT (450 IU/L,
normal <61), elevated triglycerides (4.18 mmol/L, nor-
mal <1.7), low HDL ratio (0.74, normal >1). He was
HBV and HCV negative and transaminases were nor-
mal. The probability of cirrhosis was further reinforced
by an elevated Fibrotest (0.84). To conﬁrm the diagno-
sis and the etiology of cirrhosis a liver biopsy was
performed.
Biopsy analysis revealed that the liver architecture was
preserved. In addition, there was major sinusoidal dilata-
tion with a preserved non capillarized sinusoidal endothe-
lial barrier (CD 34/CD31 negative) and a major
sinusoidal ﬁbrosis (reticulin stain) with activated a
smooth muscle actin positive hepatic stellate cells. There
was no portal ﬁbrosis, no septa formation and no argu-
ment for the diagnosis of cirrhois, steatosis or NASH.
Therefore, the ﬁnal diagnosis was cardiac hepatopathy
[3].
The elevated ﬁbrotest value in the cirrhotic range
could be explained by the elevated level of unconjugated
bilirubin (32 lmol/l, normal <18). It is also likely that
sinusoidal ﬁbrosis contributed to the high TE value
[4]. The discrepancy between the 2 TE measurements re-
mains diﬃcult to explain unless liver blood volume and
sinusoidal dilatation controlled by the cardiac pump
plays a major role in stiﬀness.
Curiously, there is no data in the literature concern-
ing TE data related to cardiac hepatopathy, and more
generally to sinusoidal diseases (SOS, haematological
disorders, amyloidosis, etc) or vascular diseases (shunts,
nodular regenerative hyperplasia, etc). The evidence we
can derive from a single case is rather weak. ‘‘ad hoc”
studies are warranted and should be programmed. This
evaluation using this rapid, painless and easy technique
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